News | 05 August 2026
Novo Nordisk lifts 2026 outlook as Wegovy pill drives global growth
The Wegovy franchise remains the leading branded obesity medication in the US market
The Wegovy franchise remains the leading branded obesity medication in the US market
PAT grows 12% to Rs. 173 crore as US formulations jump 49%; company receives 10 ANDA approvals
To support future CDMO opportunities, the company is expanding manufacturing capacity in phases, with plans to increase capacity to 1,200 KL by FY30
43 pharma units approved under RPTUAS; two common facility projects sanctioned in Solan
Regulatory clearance follows GMP surveillance inspection conducted between April 27 and May 5, 2026.
Enterprise business grows 42%, while improved product mix and higher capacity utilisation help company return to positive EBITDA despite lower revenue
API major posts strong double-digit growth in revenue and profitability, with PBT surging 61% amid robust demand for APIs and custom manufacturing
The company's EBITDA rose 38.6% year-on-year to Rs. 804.8 crore, while EBITDA margin improved to 20.03%
The company's EBITDA grew 33.5% year-on-year to Rs. 93.1 crore, with the EBITDA margin expanding to 22.0%, an improvement of 190 basis points over the corresponding quarter last year
The company's EBITDA stood at Rs. 4,417.7 crore, up 2.7% from the corresponding quarter last year, with an EBITDA margin of 28.9%
Standalone revenue reaches Rs. 206.96 crore, while profit before tax climbs nearly 18% year-on-year
Consolidated revenue from operations rises 13%, while profit before tax jumps 42% on strong operational performance
Consolidated income from operations rises to Rs. 46.63 crore, while profit more than triples sequentially on improved operational performance
Company evaluating legal options after pricing regulator seeks recovery related to Symbicort Turbuhaler for 2016–2025 period
EBITDA margin climbs to 36.6% and PAT rises 31.8% YoY, even as the company ramps up R&D spend and greenfield capacity across its API and CDMO businesses
Domestic and Africa businesses drive a strong quarter even as Middle East disruptions dent Asia sales; Equirus Securities retains REDUCE rating citing rising costs and stretched valuations
The company also reduced its net debt by Rs. 11.9 crore during the quarter, maintaining a Net Debt-to-EBITDA ratio of 1.52x despite increased working capital investments
Supported by focused therapy expansion, new product launches and improved field-force productivity, company also entered the Top 50 Indian pharmaceutical companies by market ranking
The acquisition of Aequitas Healthcare is expected to significantly strengthen Jagsonpal's specialty portfolio and provide immediate access to more than 1,000 hospitals across India
The move aimed at creating a focused API business under RPG Active Pharma comes with an initial investment of up to Rs. 243 crore
Subscribe To Our Newsletter & Stay Updated
